Sex differences in type and occurrence of adverse reactions to opioid analgesics: a retrospective cohort study

Guilherme S Lopes, Suzette Bielinski, Ann M Moyer, Debra J Jacobson, Liwei Wang, Ruoxiang Jiang, Nicholas B Larson, Virginia M Miller, Ye Zhu, Dana C Cavanaugh, Jennifer St Sauver

ABSTRACT

Objectives Sex as a biological variable affects response to opioids. However, few reports describe the prevalence of specific adverse reactions to commonly prescribed opioids in men and women separately. A large cohort was used to investigate sex differences in type and occurrence of adverse reactions associated with use of codeine, tramadol, oxycodone and hydrocodone.

Design Retrospective cohort study.

Setting Participants in the Right Drug, Right Dose, Right Time (RIGHT) Study.

Participants The medical records of 8457 participants in the RIGHT Study who received an opioid prescription between 1 January 2004 and 31 December 2017 were reviewed 61% women, 94% white, median age (Q1–Q3)=58 (47–66).

Primary and secondary outcome measures Adverse reactions including gastrointestinal, skin, psychiatric and nervous system issues were collected from the allergy section of each patient’s medical record. Sex differences in the risk of adverse reactions due to prescribed opioids were modelled using logistic regression adjusted for age, body mass index, race and ethnicity.

Results From 8457 participants (of which 449 (5.3%) reported adverse reactions), more women (6.5%) than men (3.4%) reported adverse reactions to at least one opioid (OR (95% CI)=2.3 (1.8 to 2.8), p<0.001). Women were more likely to report adverse reactions to tramadol (OR (95% CI)=2.8 (1.8 to 4.4), p<0.001) and oxycodone (OR (95% CI)=2.2 (1.7 to 2.9), p<0.001). Women were more likely to report gastrointestinal (OR (95% CI)=3.1 (2.3 to 4.3), p<0.001), skin (OR (95% CI)=2.1 (1.4 to 3.3), p<0.001) and nervous system issues (OR (95% CI)=2.3 (1.3 to 4.2), p=0.004).

Conclusions These findings support the importance of sex as a biological variable to be factored into pain management studies.

INTRODUCTION

Opioid analgesics are among the most commonly prescribed medications in the USA, with 51 opioid prescriptions per 100 persons being filled in 2017. Despite the widespread use of opioids, previous research has documented important individual differences in response to these medications.

In particular, response to opioids, including adverse reactions, may differ between males and females. Sex differences in rates of adverse reactions have been observed in adults, children, tobacco smokers, individuals with opioid use disorder and postoperative patients. In addition, these differences have been observed for different opioids, such as codeine, oxycodone, sufentanil and fentanyl.

Collectively, these data suggest that biological sex influences effects of and response to the general class of opioids. However, characterisation of the type and number of adverse reactions by opioid class and sex needs further investigation. For example, most studies investigating sex differences in response to opioids reported that women have a higher risk of experiencing nausea and vomiting after opioid use. Findings are less consistent for sex differences on respiratory depression, with some studies reporting a higher risk for women in contrast to others that observed no sex difference. Some studies reported sex-related differences of other adverse reactions, such as that women have a higher risk of experiencing reduced motor function, dizziness, negative feelings, dry mouth, hypoxia, headache and suicidal ideation, while men...
Details of the Mayo Clinic Biobank are reported in previous studies. Pharmacogenomic genotyping results were deposited into the electronic health record (EHR) for use in clinical care, and participants consented to the use of their EHR for research. Since recruitment, five participants have withdrawn their consent for future research. The Mayo Clinic Biobank population characteristics are similar to those of the general population.

Methods

Study participants

Details of the RIGHT Study have been previously reported. Briefly, 11,098 participants in the Mayo Clinic Biobank consented to participate in a study of preemptive genotyping to understand the effect of variation in genes related to drug metabolism on drug outcomes. Details of the Mayo Clinic Biobank are reported elsewhere. Briefly, the goal of the Biobank was to establish a population from which to draw controls for research studies. Therefore, patients were actively recruited from primary care departments (76%) and specialty clinics including orthopaedics (10%), executive health (4%), obstetrics/gynaecology (3%), sports medicine (1%) and the breast clinic (1%). Characteristics of the population are similar to those of the underlying population, but persons in the Biobank are older, have a higher education level, and are more likely to be of White race compared with those who did not participate. The most common medical conditions in this population are hyperlipidaemia (41%), hypertension (38%) and osteoarthritis (30%).

Prescriptions

The Rochester Epidemiology Project (REP) research infrastructure was used to identify all participants in the RIGHT Protocol who were prescribed codeine, tramadol, hydrocodone and/or oxycodone in oral form between 1 January 2004 and 31 December 2017 from a local health-care provider. We focused on these four opioids because they are commonly prescribed in the general population in the United States. The REP is a medical records-linkage system connecting collaborating clinics, hospitals, and other medical facilities in Minnesota and Wisconsin, United States, and includes data of community members who have agreed to share their medical records for research. RxNorm, a national database of normalised names for clinical drugs, was used to identify all codes for prescriptions that included the ingredients codeine, tramadol, hydrocodone or oxycodone. Formulations intended primarily to treat cough (eg, guaifenesin/
codeine) were excluded to focus on prescriptions for pain. We included both immediate release/short acting and sustained release/long acting formulations. A complete list of medications considered is shown in online supplemental file 1. To exclude instances of prevalent/chronic use prior to the study time frame, participants were excluded if they had been prescribed any of the four opioids within 2 years prior to 1 January 2004.

**Statistical analyses**

Patient characteristics at the time of the first prescription were summarised using counts and percentages for categorical variables, and median and quartiles for continuous variables. Sex as a biological variable was retrieved from the electronic medical records. Age was calculated at the date of first opioid prescription. Body mass index (BMI) was retrieved from the medical note closest to the first opioid prescription date (67% of participants had their BMI recorded within 2 years of opioid prescription). If a participant had multiple opioid prescriptions within the study time frame, then the earliest prescription was considered in the calculation of age and BMI. Sex differences in age and BMI were evaluated using Wilcoxon-rank sum tests. Sex differences in race and ethnicity were estimated using Pearson’s $\chi^2$ test with Monte Carlo simulated $p$ values based on 2000 replicates to account for small cell counts.39 Prescription rates between men and women were compared separately for each opioid using logistic regression.

Sex differences were evaluated for number and type of adverse reactions from any of four commonly prescribed opioids: codeine, tramadol, oxycodone and hydrocodone. Sex differences in reported adverse reactions were also investigated separately for each of the four opioids. Multivariable logistic regression was used to model sex differences in the risk of having adverse reactions to at least one opioid, and of having adverse reactions by each opioid separately. Finally, multivariable logistic regression was used to model sex differences in the risk of an adverse reaction in at least one of the four most common MedDRA classes (gastrointestinal, skin and subcutaneous tissue, psychiatric and nervous system) due to use of any of the four opioids. Men were considered as the reference group. Models included adjustment for age at first prescription, BMI, race and ethnicity. A two-sided significance level of $\alpha=0.05$ was adopted for all analyses. For the multivariable models, $\alpha$ was corrected to 0.0125 to account for multiple testing (Bonferroni correction).

The main analysis included only participants who were prescribed an opioid during the data collection period (figure 1A). Some participants in the RIGHT study had notes indicating adverse reactions to opioids not captured in the observed prescription data. For example, a participant had a note indicating gastrointestinal issues to oxycodone but an oxycodone prescription could not be found during the study time frame for that participant. The adverse reactions recorded outside the study coverage were assumed to have occurred due to an opioid prescribed prior to the study timeline or at a healthcare institution that was not captured by the REP research infrastructure.38 A sensitivity analysis was conducted including those participants and adverse reactions (figure 1B), that is, participants who reported at least one adverse event to an opioid prescribed outside the study coverage, akin to oversampling cases in a case–control study. For the sensitivity analysis, estimates were not adjusted for age at first prescription and BMI closest to first prescription.

![Figure 1](http://bmjopen.bmj.com/)

(A) Main analysis ($n=8,457$)

| Prescribed at least one opioid within the study coverage |
|--------------------------------------------------------|
| No | Yes |
| 8008 | 449 |

(B) Sensitivity analysis ($n=8,585$)

| Prescribed at least one opioid (regardless of whether the opioid was prescribed within the study coverage) |
|-----------------------------------------------------------------------------------------------------|
| No | Yes |
| 7466 | 991 |

Figure 1  (A) Participants included in main analysis and (B) sensitivity analysis.
RESULTS
A total of 8457 participants were included in our study, of which 449 (5.3%) reported adverse reactions. Participant characteristics and opioid prescriptions are shown in Table 1. Most participants were women (61%). Men were older (median=62 vs 55, p<0.001) and had a higher BMI (median=29 vs 27, p<0.001). Oxycodone was the most often prescribed opioid in this cohort (41% of all prescriptions). Women were more likely than men to be prescribed codeine (p<0.001) and tramadol (p=0.032). A total of 456 participants had a note in the allergy section indicating an adverse reaction to at least one opioid among the opioids included in this study (ie, codeine, tramadol, oxycodeone and hydrocodone). Seven participants had vague descriptions in their notes (eg, ‘triggers issues’, ‘didn’t like it’, ‘does not recall specifics’), thus not allowing for MedDRA classification and therefore were excluded from further analyses. Therefore, for the main analysis, a total of 449 participants were considered to have an opioid-associated MedDRA class. These participants yielded a total of 648 occurrences of adverse reaction to opioids, as participants could report adverse reactions to more than one opioid (online supplemental file 1). The four most common MedDRA classes accounted for 494 (76%) of all adverse reaction occurrences. Online supplemental figure 1 depicts the overlap in type and occurrence of adverse reactions by opioid.

Table 1 Patient characteristics

| Characteristic | Total | Men | Women | P value |
|----------------|-------|-----|-------|---------|
| Total          | 8457  | 3319 (39%) | 5138 (61%) | <0.001* |
| Age at first prescription†, years | | | | |
| Median         | 58    | 62  | 55    | <0.001‡ |
| Q1–Q3          | 47–66 | 54–69 | 44–64 | |
| Unknown        | 0     | 0   | 0     | |
| Race, n (%)    | | | | |
| White          | 7963  | 3129 (94%) | 4834 (94%) | 0.299§ |
| Black          | 44    | 22 (0.7%) | 22 (0.4%) | |
| Asian/Pacific islander | 69 | 29 (0.9%) | 40 (0.8%) | |
| Mixed/other/unknown | 381 | 139 (4.2%) | 242 (4.7%) | |
| Ethnicity, n (%) | | | | |
| Non-Hispanic   | 8359  | 3284 (99%) | 5075 (99%) | 0.476§ |
| Hispanic       | 92    | 34 (1%) | 58 (1.1%) | |
| Unknown        | 6     | 1   | 5     | |
| BMI (kg/m²)    | | | | |
| Median         | 28    | 29  | 27    | <0.001‡ |
| Q1–Q3          | 25–33 | 26–33 | 24–32 | |
| Unknown        | 1     | 0   | 1     | |
| Opioid prescriptions¶, n (%) | | | | |
| Codeine        | 1478  | 513 (12%) | 965 (14%) | <0.001** |
| Tramadol       | 3723  | 1427 (32%) | 2296 (34%) | 0.032** |
| Hydrocodone    | 4013  | 1551 (35%) | 2462 (37%) | 0.081** |
| Oxycodone      | 6467  | 2582 (59%) | 3885 (58%) | 0.614 ** |

*P value from one proportion z-test.
†First among any type of opioids considered.
‡P value from Wilcoxon-rank sum test.
§P value from χ² test (simulated p value based on 2000 replicated).
¶Opioid prescriptions between 1 January 2004 and 31 December 2017; participants could be prescribed more than one opioid.
**P value from logistic regression (Wald Z-test).
BMI, body mass index.
adverse reaction (adjusted OR (95% CI)=2.3 (1.8 to 2.8), p<0.001; see table 2). Women had a higher risk of having an adverse reaction to tramadol (adjusted OR (95% CI)=2.8 (1.8 to 4.4), p<0.001), and oxycodone (adjusted OR (95% CI)=2.2 (1.7 to 2.9), p<0.001) compared with men. The four most common types of adverse reactions were gastrointestinal (53%), skin and subcutaneous tissue (26%), psychiatric (17%) and nervous system effects (15%; see online supplemental figure 2), suggesting that adverse reactions in the nervous system often occur concomitantly with adverse reactions from other MedDRA classes.

Next, a secondary analysis was conducted by including persons who had an adverse reaction to an opioid, but did not have a prescription for that opioid in the study time frame or REP coverage (n=8585, figure 1B). Women again had a higher risk of having an adverse reaction to tramadol and oxycodone, but they also had a higher odds of reporting adverse reactions to codeine (adjusted OR (95% CI)=2.3 (1.8 to 2.8), p<0.001; see online supplemental file 1).

**DISCUSSION**

In a large cohort of patients, women were more likely to have EHR documentation in their allergy section indicating an adverse reaction to an opioid, and women reported different types of adverse reactions compared with men. Together, these results suggest that sex is an important biological variable to consider when prescribing opioids for pain management.

Overall, women were about twice as likely as men to have EHR information indicating an adverse reaction to an opioid medication after taking into account differences in prescription rates. However, the opioids included in this study are from different drug classes. Codeine, hydrocodone and oxycodone are phenanthrenes, a class of opioids characterised by a tricyclic aromatic hydrocarbon structure. In contrast, tramadol is not a phenanthrene and is involved in partial mu (μ) agonist activity in addition to central gamma amino butyric acid, catecholamine and serotonergic activities. These chemical differences may affect type and occurrence of adverse reactions. Therefore, sex differences were also examined individually for each opioid of interest. The observed sex difference for oxycodone is consistent with previous findings indicating higher rates of adverse reactions due to opioids in women. Sex differences in adverse effects to tramadol were also observed, but studies specifically investigating sex differences in adverse reactions after tramadol administration could not be found. However, these findings are consistent with general reports indicating similar sex differences in adverse reactions due to use of other non-morphine derivatives, such as sufentanil and fentanyl. Despite the large sample size, the relatively small number of outcomes for hydrocodone (n=60) and codeine (n=37) may have resulted in an inability to detect a statistically significant association.

The results also revealed that women and men had different types of adverse reactions recorded in their medical records related to opioid prescriptions. Women

**Table 2**  Sex differences in the risk of having a note in the allergy section indicating adverse reactions to opioid (men as reference group) among participants in the right study who were prescribed at least one opioid between 1 January 2004 and 31 December 2017 (n=8457)

| Characteristic                        | Total (events/prescriptions) | Sex | Men (ref) | Women | Unadjusted OR (95% CI) | Adjusted OR* (95% CI) | P value† |
|---------------------------------------|-----------------------------|-----|-----------|-------|------------------------|-----------------------|---------|
| Adverse reactions to any opioid      | 449/8457                    | 114 | 3319 (3.4%) | 335/5138 (6.5%) | 2 (1.6 to 2.4) | 2.3 (1.8 to 2.8) | <0.001  |
| Adverse reactions by opioid          |                             |     |           |       |                        |                       |         |
| Codeine                              | 37/1478                     | 10  | 513 (1.9%) | 27/965 (2.8%) | 1.4 (0.7 to 3)  | 1.5 (0.7 to 3.2) | 0.29    |
| Tramadol                             | 132/3723                    | 26  | 1427 (1.8%) | 106/2296 (4.6%) | 2.6 (1.7 to 4)  | 2.8 (1.8 to 4.4) | <0.001  |
| Hydrocodone                          | 60/4013                     | 21  | 1551 (1.4%) | 39/2462 (1.6%) | 1.2 (0.7 to 2)  | 1.3 (0.7 to 2.2) | 0.39    |
| Oxycodone                            | 266/6647                    | 70  | 2582 (2.7%) | 196/3885 (5%)  | 1.9 (1.4 to 2.5) | 2.2 (1.7 to 2.9) | <0.001  |
| Gastrointestinal                     | 236                         | 47  | (1.4%)    | 189/37 (3.7%)  | 2.7 (1.9 to 3.7) | 3.1 (2.3 to 4.3) | <0.001  |
| Skin and subcutaneous tissue         | 116                         | 27  | (0.8%)    | 89/14 (0.67%)  | 2.1 (1.4 to 3.3) | 2.1 (1.4 to 3.3) | 0.001   |
| Psychiatric                          | 77                          | 37  | (1.1%)    | 40/513 (0.8%)  | 0.7 (0.4 to 1.1) | 0.8 (0.5 to 1.3) | 0.409   |
| Nervous system                       | 65                          | 16  | (0.5%)    | 49/1478 (1%)   | 2 (1.1 to 3.5)  | 2.3 (1.3 to 4.2) | 0.004   |

*P values for multivariable (adjusted) models; †P values for the two-sided significance to account for multiple comparisons (Bonferroni correction). BMI, body mass index; MedDRA, Medical Dictionary for Regulatory Activities.
were more likely to have gastrointestinal issues, which is consistent with previous findings that women are more likely to experience nausea and vomiting. Women were also more likely than men to report issues related to nervous system (eg, migraines, dizziness) and skin and subcutaneous tissue (eg, rash, itching). These findings differ from the results of small studies indicating no sex differences in the risk of diaphoresis, skin itchings differ from the results of small studies indicating no sex differences in the risk of diaphoresis, skin itchings differ from the results of small studies indicating no sex differences in the risk of diaphoresis, skin itchings differ from the results of small studies indicating no sex differences in the risk of diaphoresis, skin itchings differ from the results of small studies indicating no sex differences in the risk of diaphoresis, skin itchings differ from the results of small studies indicating no sex differences in the risk of diaphoresis. These findings contrast with one small study reporting that women had a higher risk of reporting ‘coasting (spaced out)’ and ‘heavy or sluggish feeling’ after morphine administration, although these adjectives may not be comparable to the MedDRA class category ‘psychiatric issues’. Future research may be specifically powered to investigate sex differences in different psychological and psychiatric issues caused by opioid administration.

The observed sex differences remained statistically significant after controlling for BMI, suggesting that dosage effects due to differences in BMI did not account for the differences observed between men and women. The observed sex differences, therefore, may be due to other factors, such as the impact of sex hormones and sex-differentiated neural circuitry in the functioning of pain perception and opioid receptors, alongside sex-specific mechanisms affecting opioid dynamics and kinetics. These sex differences may also be due to associations between sex and pharmacogenomics in opioid response, but more studies are needed to understand the role of sex on genotypes affecting the metabolism of drugs. Future research may investigate the impact of sex-specific factors (eg, menopause) in the patterns of adverse reactions due to opioids.

Some participants from the RIGHT study had indications of adverse reactions to opioids to which they were not prescribed within the time frame or within the REP coverage. Results including those participants and adverse reactions were not changed except for codeine. Most participants reporting adverse reactions to codeine were never prescribed codeine in the study timeline (94%). The small number of adverse reactions for codeine in the main analysis (n=37 (6%)) may be partially due to concerns from local healthcare providers about prior reported adverse reactions, along with the availability of newer drugs. The relatively small number of outcomes for codeine may have resulted in an inability to detect a statistically significant association.

The strengths of this study include an overall large sample size and an ability to extract information directly from the EHR. In addition, we had complete follow-up information after opioid prescription. However, there are several limitations that are common to retrospective epidemiological research studies. There was the assumption that a patient only experienced adverse reactions if indications of these outcomes were found in that patient’s EHRs, and thus, this study missed adverse reactions that patients did not report to their healthcare providers (eg, patients experiencing adverse reactions without informing their healthcare provider). The results may, therefore, reflect the degree to which individuals were bothered by these symptoms rather than actual occurrence of the symptoms themselves. Moreover, men may report adverse reactions less frequently than women, and as such this reporting could bias the results if men (but not women) under-reported adverse reactions. Active, real-time follow-up of persons prescribed these medications may be needed to disentangle symptom occurrence from other factors influencing individuals’ willingness to report a symptom to healthcare providers (eg, the degree to which individuals are bothered by symptoms). In addition, opioids are frequently prescribed or used in combination with other medications (eg, adjuvant analgesics), particularly following surgical or medical procedures. Therefore, some of the reported adverse reactions may have been due to other prescriptions or other health events (such as the reason for prescription itself) that occurred at the time of the prescription and were erroneously attributed to the opioid medication. Our cohort is mostly from a non-Hispanic white population, and may not be generalisable to other groups. Our study included opioids that are commonly prescribed in the USA but that may be uncommon or not available elsewhere. Our analysis did not account for sex differences in misuse of opioids (eg, opioid use disorder, overdose) that may have contributed to different adverse reaction rates. In addition, a nocebo effect—which occurs more commonly among women—may have affected reporting of adverse reactions. For example, oxycodone has received negative publicity over the years, and the risk of adverse reactions in our study was highest among women prescribed oxycodone (5%).

We investigated sex differences in the occurrence, but not in the severity, of adverse reactions. Future retrospective studies may consider investigating differences between men and women in the misuse of opioids and severity of adverse reactions due to opioid use. Finally, although this cohort was large, some adverse effects (eg, respiratory depression) were rare, and it was not possible to assess sex differences in these adverse effects.

In summary, women had more notes in their medical records indicating adverse effects following prescription of four common opioids. In addition, the types of adverse effects experienced by women differed compared with men. Healthcare providers prescribing opioids to female patients may be more likely to advise them that they may experience adverse reactions such as nausea, constipation and pruritus. At the core of individualised medicine is the identification of factors affecting how individuals metabolise and respond to drugs. These findings, therefore, support the importance of evaluating outcomes by sex in studies of opioid prescriptions and pain management.

Acknowledgements MedDRA trademark is registered by IFPMA on behalf of ICH.
burden on younger girls with higher doses of opioids. Pain Med 2015;16:985–97.
11 Zaczynski JR, Apfelbaum SM, Perkins KA. Modulating roles of smoking status and sex on oxycodone-induced nausea and drug liking. Exp Clin Pharmacol 2013;21:103–11.
12 Lofwall MR, Nuzzo PA, Walsh SL. Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusers. Drug Alcohol Depend 2012;123:229–38.
13 Sinclair DR, Chung F, Mezey G. Can postoperative nausea and vomiting be predicted? Anesthesiology 1999;91:109–18.
14 Fillingim RB, Ness TJ, Glover TL, et al. Morphine responses and experimental pain: sex differences in side effects and cardiovascular responses but not anaglesia. J Pain 2005;6:116–24.
15 Zaczynski JR. Morphine responses in humans: a retrospective analysis of sex differences. Drug Alcohol Depend 2001;63:23–8.
16 Schnabel A, Poepping DM, Gers J, et al. Sex-Related differences of patient-controlled epidural analgesia for postoperative pain. Pain 2012;153:238–44.
17 Cepeda MS, Farrar JT, Baumgarten M, et al. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 2003;74:102–12. 102–12.
18 Daoust R, Paquet J, Lavigne G, et al. Impact of age, sex and route of administration on adverse events after opioid treatment in the emergency department: a retrospective study. Pain Res Manag 2015;20:23–8.
19 Graff KJ, Kennedy RM, Jaffe DM. Conscious sedation for pediatric orthopaedic emergencies. Pediatr Emerg Care 1996;12:31–5.
20 Sarton E, Teppema L, Dahan A. Sex differences in morphine-induced ventilatory depression reside within the peripheral chemoreflex loop. Anesthesiology 1999;90:1239–38.
21 Romberg R, Olofson E, Sarton E, et al. Pharmacokinetic-Pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 2003;98:803–13.
22 Zaczynski JR, Drum M. Psychopharmacological effects of oxycodone in healthy volunteers: roles of alcohol-drinking status and sex. Drug Alcohol Depend 2010;107:209–14.
23 Comer SD, Ashworth JB, Sullivan MA, et al. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag 2009;5:203–12.
24 Dahan A, Sarton E, Teppema L, et al. Sex-Related differences in the influence of morphine on ventilatory control in humans. Anesthesiology 1998;88:903–13.
25 Guo L, Luo M, Wang W, et al. Association between nonmedical use of opioids or sedatives and suicidal behavior among Chinese adolescents: an analysis of sex differences. Aust N Z J Psychiatry 2019;53:559–69.
26 Zaczynski JR, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology 2003;170:242–54.
27 Kaplovitch E, Gomes T, Camacho X, et al. Sex differences in dose escalation and overdose death during chronic opioid therapy: a population-based cohort study. PLoS One 2015;10:e0134550.
28 Trescot AM, Datta S, Lee M. Opioid pharmacology. Pain Physician 2008;11:S133–53.
29 Ji Y, Skierka JM, Blommel JH, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn 2016;18:438–45.
30 Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time using genomic data to individualize treatment protocol. Mayo Clin Proc 2014;89:25–33.
31 Bielinski SJ, St Sauver JL, Olson JE, et al. Cohort profile: the right drug, right dose, right time: using genomic data to Individualize treatment protocol (right protocol). Int J Epidemiol 2020;49:23–4.
32 Olson JE, Ryu E, Johnson KJ, et al. The Mayo clinic Biobank: a building block for individualized medicine. Mayo Clin Proc 2013;88:952–62.
33 Blumenthal KG, Acker WW, et al. Allergy entry and deletion in the electronic health record. Ann Allergy Asthma Immunol 2017;118:380–1.
34 Gilbar PJ, Ridge AM. Inappropriate labelling of patients as opioid allergic. J Oncol Pract 2004;10:177–82.
35 Saljoughian M. Allergy vs pseudoallergy. Opioids 2006:5–9 https://www.uspharmacist.com/article/opioids-allergy-vs-pseudoallergy
36 Liu N, Bielinski SJ, Hsing VA, et al. Information extraction framework for cohort identification using electronic health records. AMIA Jt Summits Transl Sci Proc 2013;2013:149–53.
37 St Sauver JL, Grossardt BR, Yawn BP, et al. Data resource profile: the Rochester epidemiology project (Rep) medical records-linkage system. *Int J Epidemiol* 2012;41:1614–24.

38 Rocca WA, Grossardt BR, Brue SM, et al. Data resource profile: expansion of the Rochester epidemiology project medical records-linkage system (E-REP). *Int J Epidemiol* 2018;47:368–368.

39 Hope ACA. A simplified Monte Carlo significance test procedure. *Journal of the Royal Statistical Society: Series B* 1968;30:582–98.

40 Drewes AM, Jensen RD, Nielsen LM, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. *Br J Clin Pharmacol* 2013;75:60–78.

41 McEwen BS, Milner TA. Understanding the broad influence of sex hormones and sex differences in the brain. *J Neurosci Res* 2017;95:24–39.

42 Chartoff EH, Mavrikaki M. Sex differences in kappa opioid receptor function and their potential impact on addiction. *Front Neurosci* 2015;9:466.

43 Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. *J Biomed Biotechnol* 2011;2011:1–14.

44 Lopes GS, Bielinski SJ, Moyer AM, et al. Sex differences in associations between CYP2D6 phenotypes and response to opioid analgesics. *Pharmgenomics Pers Med* 2020;13:71–9.

45 Sousa-Pinto B, Fonseca JA, Gomes ER. Frequency of self-reported drug allergy: a systematic review and meta-analysis with meta-regression. *Ann Allergy Asthma Immunol* 2017;119:e2:362–73.

46 Vambhein SM, Flaten MA. A systematic review of sex differences in the placebo and the nocebo effect. *J Pain Res* 2017;10:1831–9.

47 Osling PS, Davidson KS, Anyama BO, et al. America’s opioid epidemic: a comprehensive review and look into the rising crisis. *Curr Pain Headache Rep* 2018;22:32.

48 National Institutes of Health. *Inclusion of Women and Minorities as Participants in Research Involving Human Subjects*, 2017. Available: https://grants.nih.gov/policy/inclusion/women-and-minorities.htm